Benjamin Louis Maughan MD, PharmD

Dr. Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. Dr. Maughan completed his PharmD, cum laude, from Idaho State University in 2004, then completed an oncology pharmacy residency at Mountain States Tumor Institute in 2005. Dr. Maughan earned his MD, cum laude, from the University of Kentucky, College of Medicine in 2010. He finished his Internal Medicine residency training with the University of Utah in 2013 and subsequently completed his medical oncology fellowship at Johns Hopkins in 2016. He has been awarded the Huntsman Cancer Institute Translational Scholar Award in 2019 and was selected for the 2019 SWOG Young Investigator Training Course.

Dr. Maughan has clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and the identification of predictive biomarkers. During the fellowship, he studied predictive biomarkers in metastatic prostate cancer, specifically the role of truncated androgen receptors (AR-V7 expression) and loss of tumor suppressors (PTEN and Rb). More recently he is studying predictive biomarkers to immune therapy combinations in kidney, bladder, and prostate cancers. He is exploring novel immune therapy combinations including checkpoint inhibitors combined with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury), and targeted therapies (such as cabozantinib). He is the lead physician in a SWOG clinical trial exploring a novel treatment for patients with metastatic papillary kidney cancer.